相关实验视频

Updated: Jan 17, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

在先进软组织肉瘤的第一线治疗后进行维护

Nicolas Penel¹, Patricia Pautier², Jean-Yves Blay³

¹Department of Medical Oncology, Centre Oscar-Lambret, Lille, France; ULR 2694 - Metrics: Evaluation des technologies de santé et des pratiques médicales, CHU of Lille, University of Lille, Lille, France.

Critical reviews in oncology/hematology

|September 20, 2025

概括

维持疗法对晚期软组织肉瘤 (STS) 患者显示有前途. 在特定的STS亚型中,trabectedin和anlotinib改善了无进展生存期 (PFS),指导了未来的治疗策略.

科学领域:

在瘤学瘤学.
医学治疗学医学治疗学
临床试验分析

背景情况:

基于多克索鲁比的化疗是高级软组织肉瘤 (STS) 的标准,但有效性有限.
对STS的救援治疗通常显示效率降低.
由于治疗的局限性,研究非进展性STS的维持疗法至关重要.

研究的目的:

审查软组织肉瘤 (STS) 维持治疗的随机试验.
确定有效的维持策略,以改善无进展生存率 (PFS) 和整体生存率 (OS).
为未来STS维持疗法临床试验的设计提供信息.

主要方法:

对八项随机对照试验 (RCT) 进行STS维持治疗的系统审查.
对持续维持治疗试验的分析.
检查切换维护治疗试验的检查.

主要成果:

两项试验显示,随着持续维持,PFS有所改善:特拉贝克丁 (乳腺癌) 和安洛丁尼布 (所有亚型).
一个转换维护试验使用regorafenib改善了非adipocytic STS中的PFS.
doxorubicin/trabectedin 改善了 leiomyosarcoma 的生存状况; olaratumab 的结果在第三阶段没有得到证实.

结论:

包括特拉贝克丁和安洛丁尼布在内的维持疗法在特定的高级STS人群中提供了显著的PFS益处.
对于像多克索鲁比辛/布利祖马布这样的新组合,需要进一步的研究,需要生物标志物识别.
这一审查为设计优化的未来STS维护试验提供了基础.

关键词:

维持疗法是一种维持疗法.持续的维护持续的维护随机化试验是一种随机化试验.软组织肉瘤软组织肉瘤切换维护切换维护切换维护

更多相关视频

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...